TY - JOUR
T1 - Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch
AU - Yokoyama, Hisayuki
AU - Kanaya, Minoru
AU - Iemura, Tomoki
AU - Hirayama, Masahiro
AU - Yamasaki, Satoshi
AU - Kondo, Tadakazu
AU - Uchida, Naoyuki
AU - Takahashi, Satoshi
AU - Tanaka, Masatsugu
AU - Onizuka, Makoto
AU - Ozawa, Yukiyasu
AU - Kozai, Yasuji
AU - Eto, Tetsuya
AU - Sugio, Yasuhiro
AU - Hamamura, Atsushi
AU - Kawakita, Toshiro
AU - Aotsuka, Nobuyuki
AU - Takada, Satoru
AU - Wake, Atsushi
AU - Kimura, Takafumi
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Yanada, Masamitsu
AU - Morishima, Satoko
N1 - Funding Information:
The authors would like to thank all the physicians and data managers who provided valuable data from the Japanese Society for Transplantation and Cellular Therapy. The authors would also like to thank the staff at the Japanese Data Center for Hematopoietic Cell Transplantation for their contributions. This work was supported by JSPS KAKENHI Grant Number JP21K08363.
Funding Information:
The authors would like to thank all the physicians and data managers who provided valuable data from the Japanese Society for Transplantation and Cellular Therapy. The authors would also like to thank the staff at the Japanese Data Center for Hematopoietic Cell Transplantation for their contributions. This work was supported by JSPS KAKENHI Grant Number JP21K08363.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/7
Y1 - 2022/7
N2 - The impact of the killer immunoglobulin-like receptor (KIR)-ligand mismatch between donor and recipient in hematopoietic stem cell transplantation is controversial. Recently, it has been suggested that their effect on cord blood transplantation (CBT) differs among types of mismatched KIR–ligand and graft-versus-host disease (GVHD) prophylaxis. To investigate their role in acute myeloid leukemia (AML), mismatch of KIR2DL1, KIR3DL1, and KIR3DL2-ligand (HLA-C2, Bw4, and A3/11) were retrospectively assessed in patients undergoing CBT with GVHD prophylaxis comprising a calcineurin inhibitor plus methotrexate (CNI/MTX) or mycophenolate mofetil (CNI/MMF). In patients who received CNI/MTX, a favorable effect of KIR-ligand mismatch on relapse was noted in HLA-C2 mismatched cases (24.8% at 3 years post-CBT [no HLA-C2 mismatch, n = 1602] vs. 15.4% [HLA-C2 mismatch, n = 161], P = 0.0116). In this group, overall survival (OS) was also superior (68.2%, P = 0.0083) compared to the other group (55.0%). Multivariate analysis results supported these findings (hazard ratio [HR] 0.61 for relapse, P = 0.017 and HR 0.72 for OS, P = 0.016). However, the KIR-ligand mismatch effect was not observed in patients with KIR-ligand mismatch types other than HLA-C2 and those using CNI/MMF for GVHD prophylaxis. These results suggest that HLA-C2 mismatch in CBT using CNI/MTX as GVHD prophylaxis may improve the outcomes of patients with AML.
AB - The impact of the killer immunoglobulin-like receptor (KIR)-ligand mismatch between donor and recipient in hematopoietic stem cell transplantation is controversial. Recently, it has been suggested that their effect on cord blood transplantation (CBT) differs among types of mismatched KIR–ligand and graft-versus-host disease (GVHD) prophylaxis. To investigate their role in acute myeloid leukemia (AML), mismatch of KIR2DL1, KIR3DL1, and KIR3DL2-ligand (HLA-C2, Bw4, and A3/11) were retrospectively assessed in patients undergoing CBT with GVHD prophylaxis comprising a calcineurin inhibitor plus methotrexate (CNI/MTX) or mycophenolate mofetil (CNI/MMF). In patients who received CNI/MTX, a favorable effect of KIR-ligand mismatch on relapse was noted in HLA-C2 mismatched cases (24.8% at 3 years post-CBT [no HLA-C2 mismatch, n = 1602] vs. 15.4% [HLA-C2 mismatch, n = 161], P = 0.0116). In this group, overall survival (OS) was also superior (68.2%, P = 0.0083) compared to the other group (55.0%). Multivariate analysis results supported these findings (hazard ratio [HR] 0.61 for relapse, P = 0.017 and HR 0.72 for OS, P = 0.016). However, the KIR-ligand mismatch effect was not observed in patients with KIR-ligand mismatch types other than HLA-C2 and those using CNI/MMF for GVHD prophylaxis. These results suggest that HLA-C2 mismatch in CBT using CNI/MTX as GVHD prophylaxis may improve the outcomes of patients with AML.
UR - http://www.scopus.com/inward/record.url?scp=85129757565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129757565&partnerID=8YFLogxK
U2 - 10.1038/s41409-022-01700-y
DO - 10.1038/s41409-022-01700-y
M3 - Article
C2 - 35538140
AN - SCOPUS:85129757565
SN - 0268-3369
VL - 57
SP - 1171
EP - 1179
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 7
ER -